PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the dosing of the first patient in its Phase 1 ...

Aspire Biopharma (ASBP) announced initiation of its Phase 1 single- center clinical study of its lead therapeutic candidate, an oral ...

Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, ...

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort ...

Candel Therapeutics (CADL) announced the publication of a manuscript reporting the results of a phase 1b clinical trial exploring safety and ...

Toxicity information from phase 3 oncology clinical trials often is incomplete and interpreted in ways that minimize its ...

The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by ...

The fourth cohort of an ongoing phase 1/2 has dosed its first patient with TTX-MC138 in advanced solid tumors.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, today announced the enrollment of ...